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Background: Cystic fibrosis (CF) leads to advanced lung disease despite aggressive care. Persistent inflammation
and oxidative stress contribute to exacerbations and disease progression. Flaxseed (FS), a dietary botanical supplement
with high fiber, lignan phenolics, and omega-3 fatty acids has anti-inflammatory and antioxidant properties in murine
models of acute and chronic lung injury. This pilot study was designed to determine whether CF patients could
tolerate FS, evaluate circulating FS metabolites, and study biomarkers of lung damage, as a prelude to studying
clinical outcomes.
Methods: 10 CF patients and 5 healthy volunteers consumed 40 g of FS daily for 4 weeks with safety and tolerability
being assessed. Urine was evaluated for systemic oxidative stress and plasma for FS metabolites (enterolignans) and
cytokine levels. Buccal swabs were analyzed for gene expression of Nrf2-regulated antioxidant enzymes including
Heme Oxygenase-1 (HO-1) and NAD(P)H Quinone Oxidoreductase 1 (NQO1).
Results: All subjects completed the study without serious adverse events. Plasma levels of enterolignans were
detectable in both healthy controls and CF volunteers. CF patients were stratified based on plasma enterolignan
levels after 2 weeks of FS administration into high- (174 to 535 nM ED and 232 to 1841 nM EL) and low- (0 to 32
nM ED and 0 to 40 nM EL) plasma lignan cohorts. The low enterolignan level cohort experienced a statistically
significant drop in urinary inflammatory IsoP and plasma TNFα levels, while demonstrating higher average NQO1
mRNA levels in buccal epithelium compared to high-lignan patients.
Conclusions: This pilot study demonstrated that FS is tolerated by CF patients. FS metabolites could be detected in the
plasma. Future studies will assess appropriate dosing and target populations for FS, while exploring clinical outcomes.
Trial registration: ClinicalTrials.gov identifier: NCT02014181.
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Secoisolariciresinol diglucosideBackground
Cystic fibrosis results from malfunction of the cystic
fibrosis transmembrane conductance regulator (CFTR)
responsible for chloride transport; this therefore affects
the viscosity of mucus covering epithelia throughout the
body [1-3]. Dysfunction contributes to chronic sinusitis,
pancreatic insufficiency, and pulmonary infections with
virulent pathogens including Pseudomonas aeruginosa
and methicillin-resistant Staphylococcus aureus [4,5].* Correspondence: Denis.Hadjiliadis@uphs.upenn.edu
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unless otherwise stated.Exacerbations are characterized by inflammation mea-
sured in the blood, urine, and sputum [6-8].
Despite enzyme replacement, antibiotics, and broncho-
pulmonary hygiene – standard practice helping to improve
life expectancy in CF, exacerbations still occur and as lung
function declines, quality of life worsens and early death is
common. Dietary antioxidants have shown promise when
used in cardiovascular diseases [9]; but their use has never
been validated in CF.
Christofidou-Solomidou has investigated the use of
antioxidants in acute and chronic lung injury pioneering
animal models of acute and chronic systemic oxidative
stress to evaluate the anti-inflammatory/antioxidant potential
of naturally occurring phytochemicals [10-15]. Flaxseed (FS),al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Study Schematic. Total duration of the study was
8 weeks. Patients (10 adult cystic fibrosis patients and 5 healthy
volunteers) were enrolled at T = 0 at which time blood, urine and
buccal swabs were collected to establish baseline levels of lignans,
cytokines, isoprostanes, and 8-oxo-dGuo. Urine and blood samples
were drawn during each visit at 1, 2, 4, and 8 weeks. Buccal swabs
were performed at weeks 0, 4, and 8 (4 weeks post-FS).
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demonstrates potent anti-inflammatory, antioxidant, and
anti-fibrotic properties in murine models of ischemia-
reperfusion injury (IRI) and radiation-induced lung injury
(RILI) [10,12,14]. Omega-3 fatty acids reduce inflamma-
tion [16], while lignans are potent antioxidant phytoestro-
gens [17]. FS has been well tolerated in studies involving
patients with diabetes or prostate cancer [18,19].
Patients with CF are often excluded from dietary
studies because investigators hypothesize malabsorption
might negate beneficial properties of the study com-
pound. Serum levels of FS metabolites – enterodiol (ED)
and enterolactone (EL) can be sustained in healthy
volunteers [20,21] and we aimed to demonstrate this
with our CF cohort.
FS in murine models induces the expression of phase II
detoxification and antioxidant enzymes (Heme Oxygenase
1 (HO-1) and NAD(P)H Quinone Oxidoreductase 1
(NQO1)), transcriptionally regulated by Nrf2 binding to
the antioxidant response element (ARE) [15]. Validated
biomarkers of systemic oxidative stress, 8,12-iso-iPF2α-VI
isoprostane (IsoP) and DNA damage, 8-oxo-7,8-dihydro-
2′deoxyguanosine (8-oxo-dGuo) have been utilized to
quantify inflammation and oxidative stress in diseases
including CF and were quantified here as secondary out-
come measures [22-25].Figure 1 Study Enrollment Flow Diagram. Study enrollment opened
July 2012. 67 CF cases were reviewed to determine eligibility. All cases
were reviewed by 3 board-certified pulmonary and critical care
physicians actively caring for adults with CF. 50 patients immediately
met pre-determined exclusion criteria: actively infected, actively on
intravenous antibiotics, recently had surgery, had gut issues or were
known to be unreliable (>3 office no shows). 17 CF patients met eligibility
criteria so were interviewed during the 3-month open enrollment period.
Another 5 patients refused to participate due to distance from Philadelphia,
concerns about meeting the requirements of the study, or were just not
interested. Among the 12 patients that consented and began the trial,
another 2 withdrew for personal reasons. Between July – November 2012,
10 CF patients completed the study.We wanted to know if FS is safe and tolerable in stable
CF adults as compared to healthy volunteers. We
secondarily hypothesized that FS with its beneficial
properties would increase antioxidant gene expression.
Lastly, we hoped to measure biomarkers of chronic
inflammation and oxidative stress in urine and plasma.
This is the first study to investigate the effect of FS on
inflammation and oxidative stress in patients with CF.
Hopefully it will lead to future studies that can
demonstrate improvement in clinically relevant out-
comes, including enhanced nutrition and lung func-
tion, and decreased exacerbations.Methods
Experimental design
All fifteen subjects were enrolled to consume 40
grams of finely ground wholegrain FS for one month
provided in resealable individual pouches. On the first
visit prior to starting FS, blood, urine and buccal swab
samples were collected to establish baseline values of
FS metabolite levels, biomarkers of oxidative stressTable 1 Adult Cystic Fibrosis Patient Characteristics
Adult Cystic Fibrosis Patient Characteristics
Cystic Fibrosis Patients (N) 10
Females (N) 7
Males (N) 3
Age (years) (mean ± SD, range) 31.9 ± 10.8 (23–52)
FEV1 (%) (mean ± SD) 76.8 ± 16.8
Body Mass Index (kg/m2) (mean ± SD) 22.0 ± 2.8
Pancreatic insufficiency (N) 7
Taking Pancrealipase (N) 8
Figure 3 Safety and Tolerability of FS in Adult Cystic Fibrosis Patients. A five question survey was conducted on each clinic visit to assess: 1)
adherence to the sample diet; 2) methodology of ingestion, i.e. as smoothie, condiment, etc.; 3) presence or absence of adverse events or other
side effects; 4) changes in bowel habits (a known side effect of large volume flaxseed ingestion; and 5) subjective evaluation of mood and
perception of wellness, How do you feel today compared to before starting flaxseed…”
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expression of antioxidants HO-1 and NQO1.
Each patient consumed 40 grams of finely-ground
flaxseed daily in the manner of their choice, typically as
a primary ingredient in a smoothie. Patients returned
each week to supply blood and urine samples to trend
biomarkers of oxidative stress and trend levels of FS me-
tabolites enterodiol and enterolactone, a metabolism
requiring intact gut flora. If no side effects related to FS
ingestion were recorded by the patient, one week during
that month could be skipped in terms of supplying sam-
ples for the study – but FS was continued during that
time. After one month on FS, the patient again returned
to the clinic to supply blood, urine and now a follow up
buccal swab to establish if after one month of FS,
endogenous levels of antioxidant enzymes were boosted
by FS administration. Lastly, after another month now
off of FS, each patient was asked to return to the clinic
to supply blood, urine, and buccal swabs to this time es-
tablish if off the supplement, biomarkers of oxidative
stress and inflammation, as well as lignan levels, and
endogenous antioxidant enzyme expression reverted
back to baseline levels originally collected approximately
2 months prior.
Enrollment criteria and outcome variables
This feasibility-pilot study was conducted at the University
of Pennsylvania in accordance and after approval by the
Institutional Review Board of the same institution, which
approved the study prior to its initiation. Figure 1 displays
patient enrollment and exclusions. 10 adult patients were
recruited from the Adult CF Center and providedinformed consent. Exclusion criteria included prior or
planned hospitalization or surgical procedure within
1 month of enrollment (other than simple dental
procedure); an acute pulmonary exacerbation; history
of bowel resection, inflammatory bowel disease or distal
intestinal obstruction syndrome; receiving broad spectrum
intravenous or oral antibiotics (other than maintenance oral
azithromycin or inhaled antibiotics) within 1 month of en-
rollment; current supplementation with FS or soy deriva-
tives or allergies to them; active or prior ingestion of
Vitamin E exceeding 30 IU within 21 days; significant liver
disease (cirrhosis); significant renal dysfunction (GFR below
50 ml/hr/m2); or poorly controlled diabetes (evidenced by
HgbA1c > 7.5%).
5 healthy adult volunteers from the University of
Pennsylvania research and clinical community were
recruited and provided informed consent to serve as
controls. They were generally healthy without major
medical problems, as determined by review of their past
medical history by 2 co-investigators. No study volun-
teers could exceed age 65 or have extremes of BMI (<18
or >35).
Primary outcome was feasibility, toxicity, and tolerability
of dietary FS administration in CF as documented through
weekly surveys conducted at clinic - assessing side effects,
serious adverse events, and favorable effects of FS.
Secondary outcomes included measurements of urinary
biomarkers of systemic oxidative stress and plasma levels
of FS metabolites enterodiol (ED) and enterolactone (EL).
Blood and urine samples were obtained at 5 time points
(Figure 2): 1) Baseline – prior to FS; 2) FS – 1 Week; 3)
FS – 2 Weeks; 4) FS – 4 Weeks and 5) 4 Weeks post-FS
AB
Figure 4 Detection of Enterodiol in Plasma. Levels of plasma enterodiol were quantitated at weeks 0, 1, 2, 4, and 8 of the trial using LC/MS/MS.
No enterodiol was detected at week 0, prior to start of trial, and at week 8, which corresponds to 4 weeks after FS was discontinued. Data is
presented as plasma concentration (nM). Panel A displays comparison between healthy controls (n = 5) and all cystic fibrosis patients (n = 10).
Panel B displays comparison between healthy controls (n = 5), cystic fibrosis patients with low lignans (n = 6), and cystic fibrosis patients with
high lignans (n = 4). * signifies p < 0.05 for comparison between any time point in each respective cohort versus baseline (pre-FS).
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their choice. Urine was analyzed for F2-IsoP and 8-oxo-
dGuo levels. Plasma was analyzed for FS metabolites and
systemic cytokines. A buccal swab was obtained at base-
line, after 4 weeks of FS supplementation, and at 4 weeks
post-FS to determine antioxidant gene expression.
Managing human tissue samples
The plasma specimens were aliquoted and stored at −80°C
until lignan measurements could be performed. 5 ml of
blood was obtained prior to starting FS, approximately
15–20 ml of blood was obtained while the patient ingested
FS, and 5 ml of blood was obtained after a one-monthperiod of washout when no FS had been ingested, for a
total of approximately 30 ml of blood obtained during the
pilot. Urine samples were collected, centrifuged at 1500
RPM (297*g force) for 5 min to settle debris and also
stored at −80°C until measurements of oxidation and in-
flammation could be performed.
Buccal samples were collected using a MasterAmp
Buccal Swab Brush by Epicentre Technologies of Madison,
WI. The samples gathered by each brush tip were
deposited into an RNAlater 1.5 ml container by Ambion.
The combined buccal swab specimen in the room
temperature RNAlater vessel was transported on ice, ini-
tially stored at 4°C in the laboratory refrigerator for about
AB
Figure 5 Detection of Enterolactone in Plasma. Levels of plasma enterolactone were quantitated at weeks 0, 1, 2, 4, and 8 of the trial using LC/MS/MS.
No enterolactone was detected at week 0, prior to start of trial, and at week 8, which corresponds to 4 weeks after FS was discontinued. Data is
presented as plasma concentration (nM). Panel A displays comparison between healthy controls (n = 5) and all cystic fibrosis patients (n = 10). Panel B
displays comparison between healthy controls (n = 5), cystic fibrosis patients with low lignans (n = 6), and cystic fibrosis patients with high lignans (n = 4). *
signifies p< 0.05 for comparison between any time point in each respective cohort versus baseline (pre-FS). # signifies p< 0.05 for comparison between
any time point in each respective cohort versus baseline (pre-FS), in which mean is less than baseline.
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stored at −80°C until RT-PCR was performed, a storage
period of under one month typically.
Quantifying FS lignan metabolites and biomarkers of
oxidative stress
Circulating plasma levels of ED and EL at the five
specimen time points were determined by liquid chro-
matography tandem mass spectrometry (LC/MS/MS)
as previously described [14,26] using commercially
available standards in 95% purity (Chromadex, Inc.,Santa Ana, CA). Urinary 8,12-iso-iPF2α-VI isoprostane
levels [22] and 8-oxo-7,8-dihydro-2′-deoxy-guanosine
(8-oxo-dGuo) levels [27] were measured and normal-
ized to urine creatinine level. 8-oxo-dGuo levels were
measured by high-performance liquid chromatography-
electrospray tandem mass spectrometry [23].
Gene expression analysis
Quantitative Reverse Transcription Polymerase Chain
Reaction (qPCR) was performed using TaqMan® Probe-
Based Gene Expression Assays supplied by Applied






Gender (male) 2 (50%) 1 (17%) >0.1
Age (years) 38.8 ± 13.8 27.3 ± 5.6 0.099
Sweat chloride (mM) 74.3 ± 23.6 97.6 ± 12.0 0.070
DF508 homozygote (yes) 0 (0%) 3 (50%) >0.1
Weight (lbs) 161.0 ± 40.1 120.8 ± 18.9 0.062
BMI (Kg/M2) 23.2 ± 3.9 21.2 ± 1.8 >0.1
FEV1 (%predicted) 82.8 ± 9.5 72.8 ± 20.2 >0.1
Hemoglobin A1c 5.5 ± 0.2 6.8 ± 1.1 0.051
CF related diabetes (yes) 0 (0%) 4 (66.7%) 0.076
Pancreatic insufficiency (yes) 2 (50%) 6 (100%) >0.1
Macrolide use (yes) 0 (0%) 6 (100%) 0.005
Mucoid Pseudomonas (yes) 2 (50%) 3 (50%) >0.1
Non-mucoid Pseudomonas (yes) 2 (50%) 5 (83.3%) >0.1
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Taqman gene expression assay was selected for HO-1
and NQO1. Cells were lysed and RNA was isolated using
a commercially available kit, QIAprep Spin Miniprep
Kit, supplied by Qiagen (Valencia, CA). Total RNA was
quantified using a NanoDrop 2000 (ThermoFisher
Scientific, Waltham, MA). Reverse transcription of RNA
to cDNA was then performed on a Veriti® Thermal
Cycler using the High Capacity RNA to cDNA kit
supplied by Applied Biosystems, Life Technologies
(Carlsbad, CA). qRT-PCR was performed using 25 ng of
cDNA per reaction well on a StepOnePlus™ Real-Time
PCR System (Applied Biosystems, Life Technologies,
Carlsbad, CA). Gene expression data was normalized to
the 18S rRNA housekeeping gene and calibrated to con-
trol samples according to the ΔΔCT methods.
Statistical analysis
Pairwise comparisons tested for differences from pre-
FS supplementation. Paired t-tests (at defined α < 0.05),
comparing plasma lignans, oxidative stress biomarkers,
plasma cytokines, and buccal epithelium antioxidant
mRNA levels were performed for both healthy volun-
teers and all CF patients evaluating FS-induced changes
from baseline within each respective cohort. Upon
evaluating individual CF patient levels of plasma
lignans, we separated all CF patients (n = 10) into co-
horts with low plasma lignans (n = 6) and high plasma
lignans (n = 4). This decision was made, post-hoc, as
some patients had undetectable levels, while others had
levels similar to healthy controls. Pairwise comparisons
were then performed on these groups. Paired t-tests or
their non-parametric equivalents, Fisher’s exact test
and box plots were generated using SAS 9.3 and Statadata analysis and statistical software (release 12, Stata
Corp, College Station, TX). No corrections were made for
multiple comparisons, as only a few planned comparisons
within separate cohorts were made. Additionally this was
a small pilot study – hypothesis-generating for future
work and such corrections would not change the conclu-
sion of the study.
Results
15 subjects were enrolled over 3 months and consumed
40 g of finely-ground FS for 4 weeks. Table 1 shows the
patient demographics of the CF group. The healthy con-
trols were comparable in age and had no uncontrolled
medical problems.
Flaxseed safety and tolerability
Figure 3 shows Safety and Tolerability of FS. All subjects
completed the study. No serious adverse effects directly
related to FS were observed. No CF exacerbations,
hospital admissions, bleeding, anaphylaxis or death
occurred while supplementing with FS. A CF patient ex-
perienced new onset connective tissue disease during
the pilot; however, this flare occurred 1 month after FS
discontinuation so was deemed not directly secondary to
FS ingestion. The only complaint during supplementa-
tion was change in bowel habits. Patients and controls
experienced symptoms ranging from mild abdominal
discomfort to occasional diarrhea or constipation. Side
effects varied, occurred early in supplementation and
were self-limited.
Plasma enterolignan level comparisons
Figures 4 and 5 display plasma ED and EL levels,
respectively. Levels of ED and EL were below the limit
AB
Figure 6 Effect of FS on Urinary F2a-Isoprostane Levels as a Biomarker of Systemic Oxidative Stress. F2a-isoprostane levels, a key biomarker of
oxidative stress, were determined from urine samples collected during and after FS supplementation at week 0, 1, 2, 4, and 8. Levels were
determined by high-performance liquid chromatography-electrospray tandem mass spectrometry and normalized to urinary creatinine. Panel
A displays comparison between healthy controls (n = 5) and all cystic fibrosis patients (n = 10). Panel B displays comparison between healthy
controls (n = 5), cystic fibrosis patients with low lignans (n = 6), and cystic fibrosis patients with high lignans (n = 4). * signifies p < 0.05 for
comparison between any time point in each respective cohort versus baseline (pre-FS).
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was discontinued (week 8). Figures 4A and 5A compare
healthy controls (n = 5) and all CF patients (n = 10). A
statistically significant increase from pre-FS baseline in
ED and EL levels (p = 0.044 and 0.036 respectively) was
seen among healthy volunteers following 4 weeks of sup-
plementation. Likewise, the CF population (n = 10) had a
statistically significant increase (p = 0.038 and 0.041 re-
spectively) in ED and EL levels after 4 weeks. Figures 4B
and 5B compare healthy controls (n = 5), CF patients
with “low” plasma enterolignan levels (n = 6), and CFpatients with “high” plasma enterolignan levels (n = 4).
The 6 “low” CF patients did not significantly increase
their plasma levels during supplementation. The 4 “high”
CF patients statistically significantly increased entero-
lignan levels (p = 0.041 and 0.044 respectively) by
4 weeks.
We uncovered trends when attempting to explain why
some patients increased their lignan levels while others
did not, shown in Table 2. CF patients with elevated
plasma enterolignans were more likely to be older, have
lower sweat test and less likely to be diabetic. Additionally,
AB
Figure 7 Effect of FS on Levels of Urinary 8-oxo-dGuo as a Biomarker of Systemic Oxidative Stress. 8-oxo-dGuo, one of the major products of
DNA oxidation resulting from oxidative stress, was determined from urine samples collected during and after FS supplementation at week 0, 1, 2,
4, and 8. Levels were determined by high-performance liquid chromatography-electrospray tandem mass spectrometry and normalized to urinary
creatinine. Panel A displays comparison between healthy controls (n = 5) and all cystic fibrosis patients (n = 10). Panel B displays comparison
between healthy controls (n = 5), cystic fibrosis patients with low lignans (n = 6), and cystic fibrosis patients with high lignans (n = 4).
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taking chronic antibiotics (azithromycin or erythromycin),
while none of the 4 patients with high levels of entero-
lignans were on chronic antibiotics.
Oxidative stress biomarker modulation
Figure 6A compares average healthy control IsoP levels
to average CF patient IsoP levels. IsoP levels trended
from 8.24 ± 1.03 ng to 6.56 ± 0.99 ng after 4 weeks of
supplementation (p = 0.064). Figure 6B compares average
IsoP levels among the controls and the aforementioned
cohorts of CF patients with high versus low lignans. CFpatients with low lignan levels statistically significantly
dropped their IsoP levels from baseline (p = 0.003) after
4 weeks of FS administration. A nonsignificant trend
was seen for patients with high plasma lignan levels.
Levels of 8-oxo-dGuo are shown in Figure 7; no statisti-
cally significant differences were seen between healthy
controls and the CF patients as a whole (Figure 7A) or
in the high and low lignan subgroups (Figure 7B).
Inflammatory cytokine and immunomodulation
Figures 8A and 9A compare average plasma TNFα and
IL-1ß levels between control and CF volunteers. Overall,
AB
Figure 8 Effect of FS on Levels of Plasma Pro-Inflammatory TNFα. Levels of pro-inflammatory cytokine TNFα were determined from plasma
samples collected during and after FS supplementation at week 0, 1, 2, 4, and 8. Panel A displays comparison between healthy controls (n = 5)
and all cystic fibrosis patients (n = 10). Panel B displays comparison between healthy controls (n = 5), cystic fibrosis patients with low lignans (n = 6),
and cystic fibrosis patients with high lignans (n = 4). * signifies p < 0.05 for comparison between any time point in each respective cohort versus
baseline (pre-FS).
Turowski et al. BMC Complementary and Alternative Medicine  (2015) 15:148 Page 9 of 14the CF patients had higher average plasma TNFα.
Figure 8B compares TNFα in controls versus high lignan
versus low lignan cohorts. CF patients with low lignan
levels statistically significantly dropped (p = 0.0019)
TNFα levels after 2 weeks of FS, which was not observed
among the high lignan CF patients. Similarly, plasma
levels of IL-1ß were significantly decreased after 2 weeks
of FS administration in CF patients with low lignan
levels (Figure 9A).
Gene expression modulation
Figure 10A compares average HO-1 mRNA levels pre-
FS, after 4 weeks of FS and post-FS between the controlsand CF patients. Notably, levels of HO-1 mRNA were
statistically significantly decreased (p = 0.026) relative to
healthy controls, after 4 weeks on FS, while HO-1
mRNA levels were non-significantly increased 3.24-fold
in CF patients after FS administration. Figure 10B com-
pares fold-change in HO-1 levels among healthy control
versus CF patients further categorized based on plasma
lignan levels. Low lignan CF patients had a 4.57-fold
change in HO-1 compared with a 1.90-fold change in
high lignan CF patients. No statistical significance was
found in these comparisons. Figure 11 shows changes in
mRNA levels of NQO1, which however showed no sta-
tistically significant changes among controls and CF
AB
Figure 9 Effect of FS on Levels of Plasma Pro-Inflammatory Interleukin-1β. Levels of pro-inflammatory cytokine IL-1β involved were determined
from plasma samples collected during and after FS supplementation at week 0, 1, 2, 4, and 8. Values are reported as pg per ml of plasma. Panel A displays
comparison between healthy controls (n = 5) and all cystic fibrosis patients (n = 10). Panel B displays comparison between healthy controls (n = 5), cystic
fibrosis patients with low lignans (n = 6), and cystic fibrosis patients with high lignans (n = 4). * signifies p< 0.05 for comparison between any time point in
each respective cohort versus baseline (pre-FS).
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level status (Figure 11B).
Discussion
This study validated the safety and tolerability of FS in
stable CF patients. We demonstrated FS could be safely
added to the diet of CF patients without adding un-
wanted side effects or causing exacerbations. 100% com-
pletion of the trial occurred with no SAEs. The primary
side effect (well documented) was change in gut motility.
CF patients were split into cohorts based on plasmaenterolignan levels. The low lignan group demonstrated
statistically significant decreases in oxidative stress and
inflammatory biomarkers along with upregulation of
phase II detoxification/antioxidant enzymes.
Our results differed the ones seen by Milby et al. in
lung cancer patients undergoing radiotherapy (XRT), as
they consumed FS muffins [28]. They likewise studied
FS safety and tolerability while measuring biomarkers of
oxidative stress and inflammation. Our population,
having the freedom to ingest FS however and whenever
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Figure 10 FS Modifies Heme Oxygenase 1 Gene Expression in Buccal Epithelium. Buccal swabs were performed at week 0, 4, and 8 during the
study. Buccal epithelial cells were harvested for RNA isolation and subsequent qPCR analysis. Antioxidant gene expression levels were determined
using Taqman specific primers and probes to HO-1. Values are reported as fold change from pre-FS. Panel A displays comparison between
healthy controls (n = 5) and all cystic fibrosis patients (n = 10). Panel B displays comparison between healthy controls (n = 5), cystic fibrosis patients
with low lignans (n = 6), and cystic fibrosis patients with high lignans (n = 4). * signifies p < 0.05 for comparison between any time point in each
respective cohort versus baseline (pre-FS).
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In contrast, administering dry texture FS muffins seemed
to reduce tolerability among oncology patients with
xerostomia in Milby et.al. Oxidative stress biomarkers
also trended lower in this trial.
Intact gut flora facilitates metabolism of FS enriched
in secoisolariciresinol diglucoside (SDG) to ED and EL
[20]. Malabsorption due to pancreatic insufficiency
might have played a role in lower lignan levels. 7 of 10
patients were maintained on azithromycin therapy (initi-
ated long prior to enrollment in this study), likely having
reached homeostasis with enteric bacteria. Azithromycinalone would not have eradicated gut flora. SDG is rap-
idly converted by human intestinal microbiota to SECO
and further to the mammalian lignans ED and EL, and is
excreted in urine and feces. While no SDG was detected
in the plasma of controls and CF patients, FS consump-
tion has been shown to correlate with accumulation of
ED and EL levels in plasma [29-31].
Urinary biomarkers of systemic oxidative stress
trended lower in CF patients, particularly those who had
documented low lignan levels throughout the study. The
most dramatic change for nearly every CF patient
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Figure 11 FS Modifies NAD(P)H Quinone Oxidoreductase Gene Expression in Buccal Epithelium. Buccal swabs were performed at weeks 0, 4,
and 8 during the study. Buccal epithelial cells were harvested for RNA isolation and subsequent qPCR analysis. Antioxidant gene expression
levels were determined using Taqman specific primers and probes to Nqo1. Values are reported as fold change from pre-FS. Panel A displays
comparison between healthy controls (n = 5) and all cystic fibrosis patients (n = 10). Panel B displays comparison between healthy controls (n = 5),
cystic fibrosis patients with low lignans (n = 6), and cystic fibrosis patients with high lignans (n = 4).
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Notably, CF patients were considered “well” or in a
steady state in terms of disease, so oxidative stress bio-
markers were nearly identical to their healthy control
counterparts enrolled in the study. Importantly, the
presence of FS did not result in increased oxidative
stress on a cellular or DNA level.
The novel data gathered from the human cytokine
multiplex samples has been hypothesis generating. This
pilot study of 10 highly selected CF patients from a single
center showed favorable trends in inflammatory bio-
markers particularly in CF patients who demonstrated lowlignan levels leading us to ponder how this happened. The
inflammatory response of the innate immune system is
triggered by a TNF-α surge causing neutrophils, macro-
phages, and other professional antigen presenting cells to
perform their primary functions then present antigen to
the adaptive immune system. Chronic inflammation in CF
would be dominated by TNF-α, IFN-γ, IL-6, and IL-8 with
decreased levels of IL-10, IL-4, etc. Absolute plasma cyto-
kine levels were low (pg/ml), but trends toward decreasing
pro-inflammatory cytokine levels were observed among
CF patients. Whether this is biologically relevant requires
more study of longer duration and with greater numbers.
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the presence of high and low plasma enterolignan levels
in CF. The high lignan group had features that were very
similar to healthy controls, while low lignan patients had
different response in many measures, but improved
markers of oxidative stress. One possible explanation
could be FS was not absorbed by the low lignan patients;
however, the changes in oxidative stress markers suggest
that FS had been absorbed causing systemic effect. An
alternative explanation could be higher level of oxidative
stress in these patients and therefore faster consumption
of the lignans. This hypothesis is strengthened by the
comparison between the groups. Low lignan patients
had higher sweat tests, were pancreatic insufficient, had
genotypes associated with severe disease, with worse
spirometry. These patients are expected to have more
inflammation as a group based on their features. If true,
further studies will be needed to assess optimum FS
dose to achieve adequate lignan levels causing appropri-
ate antioxidant effect. Our patient number was too small
to make any firm conclusions. These results could be
erroneous or by chance. Another issue needing further
exploration is macrolide use in that group. It is possible
this is related to disease severity, which necessitates its
use; other possibilities are interference with lignan levels
leading to lower levels. Macrolide use was chronic and
not new in any patients. These findings will be further
explored in larger studies that are in the planning phases.
Along with direct ROS scavenging [14,15], activation
of the Nrf2 pathway and downstream effects may ex-
plain FS benefits. Buccal swabs (validated surrogates of
respiratory epithelia) [32] were collected from CF
patients as was done in prior studies of patients with
chronic oxidative stress [33-36] to quantify gene expres-
sion change from FS. The process of extracting RNA
was cumbersome, with a process standardized as much
as possible, but could account for error. Regardless, all
patients increased expression of specifically NQO1, part
of the Nrf2 family of endogenous antioxidants. Increased
NQO1 expression continued even after FS was absent
from the diet. How and why this occurred is speculative
but FS could have activated long-term oxidative stress
protection. Additional study is necessary to clarify this
interesting finding.
We are aware of our study limitations. It was a single
center, non-blinded, non-randomized trial without a
control grain for comparison and without correction
for multiple comparisons. There were imbalances in the
usage of antibiotics among patients with high and low
lignan levels, which might explain the difference in
levels, but it also might just be a marker of disease
severity. Regardless, we were able to show that in this
formulation, FS could be incorporated into the daily
medical regimen of CF patients and provide a safe,well-tolerated supplement. Lignan levels and how they
may impact oxidative stress and gene expression needs
further study.
Conclusions
In the current proof of concept pilot study we were
successful in assessing FS tolerability by CF patients and
establishing whether certain biomarkers can be mea-
sured. The study was not designed to prove that FS
works in mitigating disease which will be the focus of
larger trials. Indeed, we are in the planning stages of
larger trials to further explore our findings and assess
whether FS supplementation can lead to improvement
in clinically meaningful outcomes in CF patients.
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